New drug hope for dangerous immune overreaction after CAR-T cancer treatment
NCT ID NCT07424222
First seen Feb 22, 2026 · Last updated May 14, 2026 · Updated 13 times
Summary
This early study tests the drug ruxolitinib in 16 adults who develop a severe inflammatory condition called IEC-HS after CAR-T therapy. The goal is to see if the drug is safe and can control the inflammation. Participants take the drug twice daily for up to 8 weeks. This is a small pilot study, not a cure, but aims to manage a serious complication.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IMMUNE EFFECTOR ASSOCIATED HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS-LIKE SYNDROME (IEC-HS) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.